Skip to main content
. 2021 Sep 25;12(10):878. doi: 10.1038/s41419-021-04118-4

Fig. 6. CS-TPP-siHAT1 augments the ability of gemcitabine to inhibit pancreatic cancer cell growth.

Fig. 6

a–c PANC-1 cells were treated with CS-TPP-siHAT1 alone, gemcitabine alone or the combination for MTS assay (a), clone formation assay (b), and Annexin-V/Propidium Iodide assay (c). All data were shown as mean values ± SD (n = 3). **P < 0.01; ***P < 0.001. d–f PANC-1 cells were subcutanousely injected into the nude mice. These mice were injected intraperitoneally with CS-TPP-siHAT1 (50 μM) alone, gemcitabine (10 mg/kg) alone or the combination every 3 days. The tumor volume was measured every 3 days and all tumors were harvested for photograph and weight after 30 days (n = 5). ***P < 0.001. g All tumors were conducted caspase-3 and Ki67 analysis by IHC staining. All data were shown as means values ± SD (n = 5). ***P < 0.001.